The HIV PRN Educational Programming Committee presents a focus session on analyzing long-acting therapies for HIV Treatment and Prevention. Specific topics will include: (1) Long-acting therapies for HIV treatment, including long-acting injectables, long-acting injectables in special populations (i.e., women of childbearing age, detectable viral load, HBV co-infection), and pipeline (long-acting therapies for treatment and cure) (2) Long-acting therapies for HIV prevention, including long-acting injectables, long-acting injectables in special populations (i.e., women of childbearing age, HBV co-infection), and pipeline (long-acting therapies for prevention and co-formulated therapies with contraceptives). Several additional considerations that warrant discussion in these presentations involve older participants, usage during pregnancy, preexisting renal and hepatic complications, cardiovascular disease, and comorbid mental health diagnoses. This is particularly crucial given that these demographic groups are often excluded from initial studies. Furthermore, it is essential to delve into the assessment of interpatient pharmacokinetic (PK) variability and determine whether this variability is influenced by factors such as weight, BMI, and sex. The target audience is Pharmacists and Pharmacist Trainees across all practice settings that are interested in learning more about the use of long-acting therapies for prevention and treatment of HIV.  The purpose of this program is to highlight the extraordinary progress made in prevention and treatment of HIV with long-acting therapies while examining their use in select populations and highlighting future therapies for the prevention, treatment and potential cure of HIV.

Faculty

Moderator: Marisa Brizzi, Pharm.D., BCPS, AAHIVP Clinical Pharmacy Specialist - Pain Stewardship and HIV UC Health in Cincinnati, OH   View Biography